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Chronic Allograft Nephropathy: The Mechanisms
and Strategies
Nianqiao Gong, Xilin Chen, Zhao Ding, Changsheng Ming, Xiaoping Chen
Chronic allograft nephropathy (CAN) is the main cause of long-term renal allograft loss. It is an active but
slowly progressive injury mainly caused by alloreactivity to the graft, and further deteriorated by non-
immunologic nonspecific factors. After an overview of the pathologic characteristics of CAN based on the
Banff Working Classification, the underlying mechanisms and therapies are explored in this review, with an
emphasis on novel theories and new findings. With regard to the mechanisms, indirect antigen presentation,
ICOS-B7h costimulatory pathways, the roles of immune cells, humoral immunity, epithelial–mesenchymal
transition and fibrogenesis are paid more attention than non-immunologic factors including calcineurin inhibitor
(CNI) nephrotoxicity, ischemia/reperfusion, senescence and other various factors. With regard to therapeutic
strategy, we line up the clinical and experimental proceedings based on the mechanisms. Sufficient
immunosuppression, CNI sparing, rapamycin conversion, and administration of mycophenolate mofetil have
been applied clinically and are discussed. New experimental therapies on deletion of humoral factors, blockade
of costimulation pathway, intervention of fibrogenesis, blockade of signal transduction pathway, protection of
endothelium and tissues, and induction of accommodation are introduced together with other nonspecif ic
treatments. [Hong Kong J Nephrol 2007;9(2):58–69]
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INTRODUCTION
Chronic allograft nephropathy (CAN) is the main cause
of renal allograft loss. There is a reported prevalence
of CAN of 60–70% in protocol biopsies 1 year after
transplant [1]. With the increasing number of recipients
and the limited donor pool, transplant researchers have
shifted their focus toward the underlying mechanisms
of CAN in order to develop effective and viable
treatments in both clinical and basic areas to improve
long-term outcomes. The etiology of CAN include both
immune and non-immune causes. Furthermore, these
Hong Kong J Nephrol • October 2007 • Vol 9 • No 2 59
CAN: the mechanisms and strategies
causes interact to make diagnosis and treatment more
complicated. Herein, we use this term to mean active
but slowly progressive injury caused by alloreactivity
to the graft and further deteriorated by non-
immunologic nonspecific factors. That means the
immunologic damage, so-called chronic rejection,
provides the allograft a basic background or platform
for CAN. Based on this cognition, we focus on immune-
related rather than non-immune-related knowledge in
this review. It would be impossible to separate all the
individual parts of the mechanisms and strategies due
to their overlap; instead, we try to follow the entire
process of the immune response to elucidate the
mechanisms, with an emphasis on new clinical and
experimental strategies.
WHAT IS CAN?
CAN is usually characterized clinically as chronically
deteriorating renal allograft function, often in
combination with proteinuria and aggravation or de
novo hypertension [2]. To diagnose, pathologic evi-
dence is required and somewhat more important than
clinical data because individuals suffering from CAN
may have stable and even optimal graft function.
The current criteria for CAN are given by the Banff
Working Classification of Renal Allograft Pathology,
which originated in a meeting held in Banff, Canada
on August 2–4, 1991 [3]. The Banff 97 working
classification of renal allograft pathology is followed
worldwide [4]. Based on this classification, an adequate
specimen is defined as a biopsy with 10 or more
glomeruli and at least two arteries, with the threshold
for a minimal sample of seven glomeruli and one artery.
It is also recommended that at least two separate cores
containing cortex are obtained, or two separate areas
of cortex in the same core are included. Chronic changes
in the renal allograft can be seen in the glomeruli,
vessels, tubules, and interstitium. For allograft
glomerulopathy, the presence of double contours is the
most specific change, following the increase of the
mesangial matrix. Chronic allograft arteriopathy is
characterized by concentric thickening of the intima,
sometimes with inflammatory cells infiltrating under
the endothelium. The interstitium in CAN shows an
increase in fibrosis with corresponding tubular atrophy.
Generally, the severity of CAN is graded according to
histopathologic findings as grade I (mild), grade II
(moderate) or grade III (severe), which is defined by
the mild, moderate or severe interstitial fibrosis (ci0 to
ci3) and tubular atrophy (ct0 to ct3). CAN grade I
requires minor changes (equivalent to ci1, ct1), CAN
grade II requires moderate changes (ci2/ct2, ci1/ct2,
ci2/ct1), and CAN grade III requires severe changes
(ci3/ct3, ci2/ct3, ci3/ct2). Tubulointerstitial and
glomerular damage, once established, are irreversible,
resulting in declining renal function and graft failure.
The term “irreversible point”, suggested by Tullius et
al in a rat CAN model, emphasizes that there are two
phases in CAN progression based on clinical and
pathologic alterations [5]. In an outstanding 10-year
clinical study, two distinctive phases of injury were
evident as CAN evolved [6]. An initial phase of early
tubulointerstitial damage from ischemic injury, prior to
severe rejection and subclinical rejection, predicted mild
disease by 1 year. Beyond 1 year, a later phase of CAN
was characterized by microvascular and glomerular
injury. By 10 years, severe CAN was present in 58.4%
of patients, with sclerosis in 37.3% of glomeruli.
The 8th Banff conference on allograft pathology was
held in 2005, and the updated classification tries to
eliminate the diagnostic term “CAN” because it has
been used for all causes of chronic renal allograft
dysfunction with fibrosis, hindering accurate diagnosis
and appropriate therapy. With the recognition of the
entity of chronic antibody-mediated rejection and based
on new pathologic knowledge, the traditional CAN has
been divided into three parts: (1) chronic active
antibody-mediated rejection; (2) chronic active T cell-
mediated rejection; (3) interstitial fibrosis and tubular
atrophy with no evidence of any specific etiology [7].
Again, we can find that these categories depend on the
causes of both alloantigen and non-alloantigen. In
the clinical setting and even in the animal kidney
transplantation setting, these categories are usually
present together so that there is still a need for the term
“CAN” for easier discussion until a more precise term
can be settled on.
THE UNDERLYING MECHANISM OF CAN
CAN is an active procedure that is closely related to
immunoreactivity. The underlying mechanisms are
detailed below, according to the sequence of the entire
immune response, tissue and cell pathophysiology, and
nonspecific factors. All causes lead to damage, followed
by fibrogenesis, which are the central characteristics
of CAN.
Human leukocyte antigen matching
No doubt, human leukocyte antigen (HLA) matching
between donor and recipient has a strong effect on renal
allograft long-term survival. In humans, HLA-matched
grafts have an estimated half-life of 12.4 years
compared with 8.6 years for HLA-mismatched grafts
[8]. The well developed cross-reactive group (CREG)
matching is associated with a reduced frequency of late
acute rejection episodes and improved graft function
at 2 years [9], while sharing less CREG is correlated
with inferior long-term graft survival [10].
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Panel reactive antibodies
Panel reactive antibodies (PRA) represent the overall
antibody level against a particular human population
in the given individual. A high PRA value in a recipient
candidate usually indicates a high possibility of an
immune response to a random donor from that pop-
ulation. Although alloantibody level represented by
cross-match prior to transplantation could be negative,
a high PRA before and after grafting remains a high
risk factor for progression of CAN. It has been reported
that with the decrease in blood transfusions since the
introduction of erythropoietin, there has been a
substantial decrease in mean PRA value, resulting in
longer-term survival [11]. In his humoral theory of
chronic rejection, Terasaki believes that elevated PRA
in the recipient after transplantation is one key factor
in the progression of CAN [12,13].
Antigen presentation
Antigen presentation to T cells plays a central role in
the immune response. Antigen presentation directs the
following immunoreactivity model and regulates
ongoing chronic rejection. Based on different antigen
processing and presenting mechanisms, T cells
recognize foreign HLA antigens via direct or indirect
pathways. In the direct pathway, donor-derived antigens
are presented on donor-derived professional antigen-
presenting cells (APCs) to recipient T cells, which
mainly results in the activation of CD8+ T cells and
thus T cell effector functions. Alternatively, indirect
presentation is mediated by uptake of donor antigens
by recipient-derived APCs graft-infiltrating and/or in
the secondary lymphoid organs. Indirect antigen
presentation has been suggested to play an important
role in the induction of chronic rejection [14,15].
Indirect presentation might result in activation of B cell
responses and thus production of alloantibodies [14,
15]. Furthermore, the indirect pathway might be subtly
related to chronic CD4+ T cell-mediated injury to the
allografts; among the recognized antigens could be
subdominant and/or cryptic epitopes derived from the
dominants processed by non-professional APCs or
APCs in non-draining lymphoid compartments or from
de novo exposed antigens by immunologic damage in
tissue debris, termed epitope spreading. At a later stage,
the immune response diversifies into multiple
determinants of the same or other antigens [16,17].
Moreover, non-professional APCs may induce a unique
subset of cytotoxic CD8+ T cells (CTL) that are less
efficient at cell killing, partly explaining a chronic
alloresponse (allograft arteriopathy) to the persistence
of alloantigens [18–20].
For full activation and proliferation, T cells need
at least two signals: the first signal, which is mediated
through the T cell receptor, and the second, co-
stimulation, signal, which is transferred through cell
surface receptors by interaction with their ligands
(CD28-B7, CD40-CD40L, ICOS-B7h, LFA-1-ICAM-
1) [21,22]. The CD28-B7, CD40-CD40L and ICOS-
B7h costimulatory pathways are intimately linked,
because the IgG switching defect in ICOS knockout
mice can be rescued by CD40 signaling and ICOS
costimulation has been shown to increase CD40L
expression, suggesting that ICOS is upstream of
CD40-CD40L in the same pathway [23]. Although the
CD28-B7 and CD40-CD40L pathways are thought to
be important in acute rejection [24], there is evidence
to support their roles in modulating chronic rejection,
including CAN, in experimental models. Both CD40-
CD40L and ICOS-B7h contribute to CAN [25], but
the ICOS-B7h pathway more profoundly responds to
CAN. First, B7h is constitutively expressed on B cells
and is inducible on monocytes, dendritic cells,
fibroblasts, and endothelial cells (ECs) [26,27].
Second, ICOS-B7h interactions are important for the
development of effector CD8+ and CD4+ cells [28,
29]. Furthermore, this pathway is shown to modulate
not only T-helper 1 (Th1)-dependent response but also
Th2 signaling [28,29]. Moreover, the antigen in the
context of major histocompatibility complex with the
appropriate T cell receptor in the presence of CD40-
CD40L and ICOS-B7h costimulation results in
activation of B cells and antibody production [30,31].
This pathway is more responsible for the late immune
response, memory lymphocyte reaction and chronic
rejection [23].
Cellular immunity
There is evidence to show that CD4+ and CD8+ T
cells play roles in recipients with CAN. In research
on the contribution of CD4+ and CD8+ T cells and
interferon-a to CAN in humans, Obata et al found that
the Th1 response mediates both acute and chronic
rejection [32]. Our data and those of others show that
the Th2 response, which directs immune reaction to
shift to humoral immunity, may play a more sig-
nificant role in CAN than Th1 [33,34]. Koch et al
proved that adoptive transfer of primed CD4+ T cells
induced a pattern of CAN in a nude rat model [35].
Kuo et al provided evidence for the seminal role of
CD4+ T cells in the pathogenesis of obliterative airway
disease, which represents chronic rejection in the lung
graft [36]. It has been postulated that the chronicity
of the vascular injury may be due to a delayed-type
hypersensitivity response that is intrinsically
ineffective in eliminating donor antigens that are
located on ECs lining the vessels [37,38]. The
activated CTLs can lyse the target cells and result in a
tissue lesion or scar which is closely related to the
following fibropathogenesis. As mentioned above, the
insufficient cell killing of the CTLs could reduce
chronic allograft arteriopathy [18–20]. Furthermore,
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CD103+CD8+ T cells have the capacity to combine
with tubular epithelial cells via their counter-receptor
E-cadherin, inducing the process of epithelial–
mesenchymal transition (EMT) and, later, CAN [39].
Moreover, infiltrating inflammatory cells (macro-
phages, natural killer cells, neutrophils) promote the
process of CAN by secreting a variety of cytokines and
growth factors for local damage [40].
Humoral immunity
There is accumulating evidence to indicate that humoral
immunity plays a role in CAN. C4d is one of the
degradation products of complement component C4
that remains covalently linked to the tissue after
activation. C4d is thought to be more stably deposited
compared to IgG, and it is therefore frequently used as
a marker for humoral rejection [41,42]. Glomerular C4d
deposits have been found in about 16% of renal allograft
biopsies [43], whereas with transplant glomerulopathy,
the majority of patients have glomerular C4d deposits
[44]. The presence of C4d deposits in allograft biopsies
seems to be an independent predictor of CAN [45].
Humoral responses can be directed against HLA or
non-HLA antigens of the graft. Renal transplant
recipients with anti-HLA antibodies are 5–6 times more
likely to develop chronic rejection and lose their grafts
[46]. De novo anti-HLA antibodies post-transplantation
have also been correlated with chronic rejection and
the poorest graft outcome [47,48]. In addition, almost
all patients with chronic rejection have had circulating
antibodies against HLA antigens, but not necessarily
donor HLA antigens [49]. Antibodies reactive with
mesangial cells and glomerular basement membrane
antigens were also found in the development of chronic
rejection [50–52]. The antigens involved were identified
as the heparan sulfate proteoglycan perlecan and the
_1 chain of collagen type VI in association with the _5
chain in the glomerular basement membrane [51,52].
Furthermore, antibodies against non-HLA antigens on
ECs could result in apoptosis or proliferation, which
accelerates the process of CAN [53,54].
Acute rejection/subclinical rejection
It is clear that there is a close relationship between acute
rejection and chronic rejection. Acute rejection episodes
within the first 3 months may have no effect on chronic
rejection, whereas acute rejections occurring after 6
months confer the greatest risk [55]. Ten-year graft
survival rates censored for causes of graft loss other
than chronic rejection were 94%, 86%, and 45% for
patients without an acute rejection episode, with early
acute rejection episodes, and with late acute rejection
episodes, respectively [9]. The estimated half-life for
cadaveric transplants is shorter in patients who have
experienced an acute rejection episode than in those
who have not, 6.6 years versus 12.5 years [56].
Compared with acute rejection, subclinical rejection
may be more dangerous for patients as the clinical
alteration is mild and often undetectable due to the
kidney’s potent compensation capability. In this case,
the mild tubulitis, intimal arteritis and infiltrating
lymphocytes lead to slow but persistent damage,
inducing fibrogenesis.
Proinflammatory factors, chemokines and growth
factors
It has been shown that proinflammatory mediators,
cytokines and multiple chemokines are involved in
alloreactivity. Cytokines secreted by lymphocytes,
macrophage, and by the cells of inflamed tissue could
be responsible for the formation of arteriosclerotic
lesions. Leukocyte attraction and trafficking to sites of
immune reactions are controlled by chemoattractant
cytokines and interleukins. The chronic antigenic
stimulation of T cells by graft HLA antigens results in
the production of cytokines that damage the vascular
endothelium. ECs may then secret growth factors that
induce the proliferation of smooth muscle cells (SMCs)
and the migration of myocytes from the media into the
intima.
Graft endothelium
The vascular endothelium is the first place of donor–
recipient contact. ECs could be injured and then
activated to express more E-selectin, intercellular ad-
hesion molecule 1 (ICAM-1), vascular cell adhesion
molecule 1 and nuclear factor kappa B, and secrete
proinflammatory factors and endothelin (ET). Elevated
ET levels are associated with inflammation and immune
responses as well as with transplant-associated diseases,
contributing to cell activation and growth. ET
expression is stimulated by chemokines, and ET itself
stimulates the synthesis of chemokines under certain
conditions [57]. ECs are also the first target of
alloreaction, resulting in changes in morphology and
function of ECs and then apoptosis, which participates
in CAN progression.
Cell proliferation and fibrogenesis
Graft vasculopathy is an intimal fibroproliferative
process; intimal hyperplasia due to the accumulation
of SMCs is a key factor in the pathogenesis. Both
immune- and drug-induced vascular lesions are
characterized by an inflammatory response that is
accompanied by the release of cytokines and growth
factors that stimulates SMC migration to the intima.
SMCs are then driven by the inflammatory milieu to
further activation, leading to proliferation and
deposition of extracellular matrix and resulting in
intimal thickening, flow obstruction, and tissue is-
chemia. Most of the proliferating cells in early neo-
intimal development are graft-derived SMCs [58,59].
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In the late stage, however, the SMCs are host-derived:
SMCs or myofibroblasts migrating into the graft from
adjacent vessels [60], the progenitor cells released
from vasculature and reaching the graft via circulation
[61,62], and bone marrow-derived progenitor cells
reaching the graft via circulation [63,64]. In the ves-
sels of the kidney suffering from CAN, the
pathophysiology is similar [65]. But regarding
interstitial fibrosis, the fibrogenetic cells originate
from several places: 14–15% are bone marrow-derived
fibroblasts, 36% are derived from tubular EMT, and
the rest is from the proliferation of native local fi-
broblasts [66]. During the EMT process, the tubular
epithelial cells lose the epithelial cell characteristics,
gradually acquire mesenchymal cell characteristics,
and finally transdifferentiate toward fibroblasts,
resulting in interstitial fibrosis. Activated CD4+ and
CD8+ lymphocytes, macrophages or CD103+ cells (a
regulatory T cell marker), and even calcineurin
inhibitor (CNI) nephrotoxicity, are all likely to be
responsible for this transition [33,39,67,68]. Fur-
thermore, some signal transduction pathways, in-
cluding p38, ERK1/2, STAT, PKC, and E2A [68–71],
are involved in EMT. Strutz and Muller have de-
clared that transdifferentiation has come of age [72].
CNI nephrotoxicity
CNI improves early graft survival significantly.
However, the balance between preventing immunologic
allograft loss and the management of CNI-related
nephrotoxicity is still an issue in renal transplantation.
CNI initiates and sustains vascular injury and tissue
ischemia, characterized by nodular hyaline deposit
on the outer part of the arteriole [4], resulting in acute
and chronic effects ranging from vasoconstriction to
activation of ECs, significant increase in growth factors
and cytokine synthesis and release, inhibition of
endothelial nitric oxide production and extracellular
matrix accumulation, cell migration, and proliferation
[68,73,74].
Brain death and ischemia/reperfusion
Brain death and ischemia/reperfusion (I/R) may
culminate clinically in delayed graft function (DGF),
which is defined as a requirement for dialysis during
the first week after transplantation, and trigger an
inflammatory cascade with upregulation of cytokines,
and adhesion and HLA-DR molecules [75,76]. This
injury increases graft immunogenicity leading to more
early acute rejection episodes. Although fully recovered
DGF without acute rejection episodes may not
necessarily be detrimental for long-term graft survival
[77], according to the UNOS (United Network for
Organ Sharing) database of almost 89,000 cadaveric
donor transplant recipients, DGF is associated with a
small increased risk of CAN [78].
Senescence
Cells in senescence show alterations in shape,
expression of extracellular matrix metalloproteinases
(MMP) and cytoskeletal collagens with several
characteristics including shortened telomeres, increased
expression of specific tumor suppressor genes, and
increased activity of senescence-associated `-
galactosidase (SA`-gal) [79]. The cell cycle inhibitors,
p16 and p21, have been studied in relation to cellular
senescence, and both are thought to be involved in G1
arrest [80,81]. In this case, the biological age of the
chronically rejected kidney is higher than the
chronological age [80,81].
Other non-immunologic factors
Many other factors could have effects on CAN
progression, including cadaveric donor, old donor age,
renal insufficiency, cytomegalovirus infection,
overweight, recipient smoking, non-compliance, hy-
pertension, proteinuria, hyperlipidemia, diabetes and
so on. Moreover, young age is also a risk factor that is
associated with a relatively high state of immune
responsiveness to alloantigens.
THE STRATEGIES: WHAT WE CAN DO
Even if the contributing factors to CAN can be
identified, not all of them can be interrupted prior to
and after grafting. In many settings, transplant
candidates have no better choice for donor HLA typ-
ing, cadaveric, old age, and renal insufficiency. After
operation, these factors are not amenable to therapy.
Indeed, clinicians can only do what they can. In the
section below, we focus on the practical clinical and
experimental strategies based on the corresponding
mechanisms.
Immunologic matching
In theory, the ideal donor is one with an identical
immunologic background as the candidate. In reality,
this will always be limited by the donor pool. Realistic
requirements are a negative cross-match and a HLA/
CREG mismatch that is as low as possible. If the PRA
value of the candidate is higher than expected, some
preconditioning treatment such as tacrolimus/
mycophenolate mofetil (MMF) administration, high-
dose intravenous immunoglobulin (IVIg) and
immunoabsorption is helpful, not only for acute
rejection but also later for CAN.
Sufficient administration of immunosuppressant
against acute rejection/subclinical rejection
The extent of the alloresponse is a balance between
the immunogenici ty  of  the graf t ,  recipient
responsiveness, and the level of immunosuppression.
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After transplantation, a sufficient level of immu-
nosuppression is definitely required to prevent the
onset of acute rejection that may destroy both the
function and the structure of nephrons and generate a
high risk for CAN. But in some clinical settings,
including consideration of the side effects of immu-
nosuppression, DGF, and economic problems, the
serum level of immunosuppressant is relatively low
(although the value is within the general therapeutic
window), which is the main cause of the initiation of
subclinical rejection. It is tempting for the patient and
clinician to ignore the underlying progressive damage
of the mild activated immune reaction due to a
satisfactory serum creatinine level. In a small-scale
prospective clinical study, up to 50% of allograft kid-
ney biopsy samples were found to have mild acute re-
jection with lymphocyte infiltration; high-dose
methylprednisolone bolus treatment for 3–5 days
could often stabilize kidney function and, in some
cases, decrease creatinine level to some extent [67].
A sufficient level of immunosuppression is crucial
in preventing CAN; it can be easily achieved, but per-
haps we just need to pay more attention to it.
CNI sparing and rapamycin conversion
Although in some recipients on cyclosporine, conversion
to tacrolimus (a potent agent that suppresses both cellu-
lar and humoral immunity) resulted in sustained
improvement in renal function [67], CNI sparing
strategies are thought to be of benefit for CAN patients.
Three main protocols have been investigated: CNI
minimization, CNI withdrawal, and complete avoidance
of CNI [82]. In regimens based on rapamycin, CNI
withdrawal is a safe strategy, achieving an improvement
in renal function, histology, and graft survival.
Rapamycin may have the ability to reduce the rates of
chronic rejection by further reduction of the incidence
of acute rejection episodes, and inhibit the proliferation
of SMCs and fibroblasts to reduce intimal hyperplasia
in immune and non-immune models of vascular injury.
Rapamycin introduction dramatically reduced intragraft
_-smooth muscle actin expression, whereas reduction
in CNI doses resulted in a significant decrease of this
marker of fibroblast activation in the 2-year biopsy [83].
In vitro studies showed that rapamycin, compared with
cyclosporine, tacrolimus, mycophenolic acid, and
deoxyspergualin, is the only immunosuppressant with
pronounced inhibitory effects on growth factor-
stimulated SMC proliferation [84]. In addition,
manifestations of chronic rejection are also inhibited by
the novel antiproliferative macrolide everolimus (a
rapamycin derivative) in preclinical models [85].
Administration of MMF
MMF can inhibit the proliferation of T cells and B cells
[86]. The effects of this drug on T cells are not via the
IL-2 pathway or transduction signals but via inhibition
of downregulation of p27kip1 [87]. MMF inhibits the
mixed lymphocyte reaction response to alloantigen in
vitro [86] and inhibits induction of CTLs and allogenic
rejection in vivo [88]. MMF probably mainly inhibits
the early stage of proliferation and differentiation of B
cells rather than generation of antibodies by plasma
cells, a long-term benefit for CAN [89]. It also inhibits
dendritic cell maturation and antigen presenting [90].
Besides stabilizing ECs, inhibiting recruitment of
mononuclear cells to the allograft, and decreasing nitric
oxide and oxidant induced by cytokines, MMF
interestingly inhibits the proliferation of SMCs without
fibrogenesis, which directly attenuates the graft
arteriopathy of CAN [91–93].
Deletion of humoral factors
The circulating antibodies against HLA and non-HLA
(glomerular basement membrane antigens, EC
antigens) initiate/aggravate the kidney damage of CAN.
To date, there are several choices to remove the
circulating antibodies: plasmapheresis (PP), high-dose
IVIg, immunoabsorption, splenectomy, and anti-CD20
antibody application. PP, IVIg and immunoabsorption
can decrease antibody titer directly. Splenectomy and
anti-CD20 antibody application can reduce B cell mass
and incapacitate immune surveillance and antigen
presentation to downregulate the antibody titer in-
directly. But for reasons of economy and convenience,
short-term and high-dose IVIg administration may
represent the best choice clinically.
Blockade of costimulation pathway
Blockade of various costimulation pathways have been
used in order to prevent both acute and chronic rejection.
Both CTLA4-Ig and blocking anti-CD28 monoclonal
antibodies have been found to prevent the development
of chronic rejection [94,95]. Late treatment of recipients
with CTLA4-Ig to block CD28-B7 interactions also
attenuated antibody responses [95]. But florid chronic
rejection lesions have been reported in long-term
surviving cardiac allografts after the blockade of the
CD40-CD40L pathway alone or in combination with
CD28-B7 blockade [96–99]. Guillot et al found that
prolonged blockade of CD40-CD40L interactions by
gene transfer of CD40Ig resulted in long-term allograft
survival and donor-specific hyporesponsiveness, but did
not prevent chronic rejection [98]. Meanwhile, there
has been renewed interest in the ICOS-B7h pathway.
In nonhuman primates, blockade of CD40L did not
affect the production of anti-donor antibodies, but
blockade of B7h-ICOS costimulation demonstrated a
key role in the prevention of chronic rejection [100]. In
addition, decreased anti-donor alloantibodies have been
found upon ICOS blockade [101]. The CD40Ig+ anti-
ICOS group showed significant decreased graft
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infiltration, decreased anti-donor CTL activity, and
decreased alloantibodies compared with the CD40Ig-
treated group [25].
Treatment against proinflammatory factors,
chemokines and growth factors
Proinflammatory factors and chemokines are generated
by lymphocytes and damaged graft tissues. Meanwhile,
the local immunologic milieu attracts activated immune
cells, including T cells, B cells and macrophages, and
results in more severe lesion and the later CAN. Neto
et al demonstrated that carbon monoxide inhibited the
progression of fibrogenesis and the deterioration of
renal allograft function of established CAN via its anti-
inflammatory function [102]. In a rat CAN model, Yang
et al identified that targeting of macrophage activity
by adenovirus-mediated intragraft overexpression of
TNFRp55-Ig, IL-12p40 and vIL-10 could ameliorate
adenovirus-mediated chronic graft injury, whereas
stimulation of macrophages by overexpression of
interferon-a accelerated the injury [103]. Keane et al
found that IL-13 gene expression was markedly elevated
within allografts and associated with macrophage
infiltration and activation in a profibrogenic milieu prior
to developing fibrosis [104]. Schnickel et al found that
a combination of CXCR3 and CCR5 blockade holds
great promise in the control of chronic rejection and
markedly decreased intimal thickening in a rat
heterotopic heart transplantation model [105]. Inhi-
bition of various growth factors is also effective in the
treatment of CAN. Daniel et al demonstrated the
antiangiogenic function of A20 in ECs via blockade of
vascular endothelial growth factor (VEGF)-mediated
phosphorylation of PKC`II and ERK1/2, and suggested
that antiapoptotic and anti-inflammatory effectors could
make A20-based therapies ideal for the treatment and
prevention of transplant arteriosclerosis [106].
Moreover, Nykanen et al identified VEGF-driven
interplay of inflammation and primitive capillary
angiogenesis in chronic rejection to control pathologic
microvascular and arterial remodeling in cardiac
allografts [107]. Recently, our team found that the
migration and proliferation of SMCs could be inhibited
after downregulation of platelet derived growth factor
(PDGF)-BB by Adanti-ERK gene transfer (data not
published). We also found that administration of high-
dose aspirin could decrease PDGF expression in the
vascular allograft so as to ameliorate allograft
arteriopathy (data not published). Herrero-Fresneda
et al found that hepatocyte growth factor gene
electrotransfer attenuated renal allograft scarring by
interfering with the profibrotic inflammatory
mechanism [108]. In summary, regulation of the
proliferation, migration and secretion of fibrogenic
cells by cytokine and growth factor blockade is an
effective option to treat CAN.
Signal transduction pathway blockade
Healy et al proved that EMT was accompanied by
sustained activation of p38 and p42/44 (ERK1/2)
kinase, which are typically associated with a pro-
liferative state [69]. Li et al also demonstrated that
advanced glycation end products induced tubular EMT
through the ERK1/2 kinase signaling pathway [109].
Our group found that antisense ERK1/2 oligo-
deoxynucleotide gene therapy could attenuate graft
arteriosclerosis of aortic transplant in a rat model
[110]. We also observed that adenovirus-mediated
antisense-ERK2 gene therapy attenuated CAN [111].
The treatment downregulated the expression of related
genes (IL-2, ICAM-1), lessened inflammation, and
improved graft histology/function. Whether the
interruption of the ERK1/2 pathway protects allograft
via inhibition of EMT and fibrogenesis requires fur-
ther investigation. In an ex vivo study, Slattery et al
demonstrated that overexpression of E2A proteins could
induce EMT in human renal proximal tubular epithelial
cells, suggesting a potential role in renal fibrosis [68].
To date, the number of investigations on signal
transduction pathway blockade against CAN is low,
and many more activities remain for further study.
Protection of endothelium and tissues
Maintaining a stable endothelium could be a helpful
strategy. ET receptor blockade induced pronounced
inhibition in circulating levels of IL-1ra and TNF-_
and changes in gene expression of IL-1ra, IL-10 and
IL-6 in tissue-specific patterns that occurred
independent ly  of  the development  of  graf t
arteriosclerosis [57]. Antioxidative stress treatment is
also an alternative. Djamali et al found in the CAN
tissues tubular O2–, endothelial nitric oxide synthase(NOS) and inducible NOS, and interstitial collagen I,
III and O2– levels were significantly increased in CAN-
associated EMT [112]. They also demonstrated that
oxidative stress could be a unifying injury pathway in
experimental and human CAN, and graft infiltration
macrophages might be an important source of reactive
oxygen species through the NADPH oxidase pathway
[113].
Other therapies against fibrogenesis
Because fibrogenesis is a central mechanism in the
progression of CAN, all treatments, from prevention
of acute rejection to antioxidant therapy, basically aim
to attenuate damage and ameliorate fibrosis remodeling.
The MMP family has complex roles in CAN, according
to the different members. MMP-2 and MMP-9 can
degrade type IV collagen to enhance CAN progression
[114,115]. MMP-3 promotes SMC migration to the
intima [116]. Local activity of MMP-2 can be sufficient
to initiate EMT, possibly through a mechanism
involving local proteolytic activation of transforming
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growth factor-` [117]. So, MMP-based therapy might
be valuable for CAN. Bone marrow protein-7 can also
inhibit EMT via the transforming growth factor-`
pathway [118], so it might also be a candidate strategy.
Induction of accommodation
The term accommodation is more commonly used in
xenotransplantation than in allotransplantation. But
this phenomenon does exist in kidney allografts.
Accommodation is when the graft survives well even
in the presence of antigraft antibodies, which indicates
that the graft is protecting itself by some subtle
mechanisms: elevated expression of antiapoptotic
factors or complement regulatory factors. In human
renal acute rejection, high expression of bcx-xL and
upregulation of Duffy antigen receptor have been
identified [119,120]. In allograft with CAN, the
complement regulatory factor protectin (CD59) and
decay accelerating factor (CD55) were also found to
contribute to accommodation and to the attenuation of
damage [121]. Semiletova et al introduced allochimeric
RT1.Aa class I major histocompatibility extracts in a
cardiac allograft chronic rejection setting and found that
the treatment altered humoral immunity and induced
vascular accommodation according to the improved
level of Bcl-2/Bcl-xL gene expression [122]. We found
that overexpression of HO-1 gene could markedly
protect rat kidney allograft against CAN at 3 months
and 6 months after grafting [33]. At present, research
on the effects of antiapoptotic factors or complement
regulatory factors to protect allografts from CAN is
insufficient and may be the next focus.
OTHER INTERVENTIONS
Non-immunologic measures to halt or retard the
progression of CAN have focused on aggressive control
of blood pressure, proteinuria, hyperlipidemia and
diabetes. Treatment of hypertension with calcium
channel blockers, beta-blockers and angiotensin-
converting enzyme inhibitors (ACEI) have similar
antihypertensive efficacy after renal transplantation and
are often used in combination to achieve adequate
control. Significant reduction in proteinuria has been
reported as a beneficial effect of ACEI and angiotensin
II receptor antagonists in clinical transplantation.
Patients taking ACEIs enjoy less severe CAN overall
and longer graft survival [123]. Frequently, statins are
used to treat hyperlipidemia, especially in patients
taking rapamycin. After transplantation, some patients
may suffer from diabetes due to the immunosuppressant
(especially tacrolimus). In this situation, glucose control
or medication conversion should be considered. Anti-
virus treatment, diet, weight control, no smoking and
good compliance are suggested in certain settings.
Drugs that improve the microcirculation are also
helpful. In addition, molecule interruption against
shortened telomeres, SA`-gal, p16 and p21 could be
designed for the senescent allograft in future.
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